Knight Therapeutics (KHTRF) 5.7128 $KHTRF
Knight Therapeutics Inc. Acquires Orphan Canada Inc. and Expands Business Development Capacity
Marketwire - Tue Sep 02, 7:33AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into an asset purchase agreement with Orphan Canada Inc. ("Orphan"

related to the Canadian rights for ATryn(R) and PHOTOFRIN(R) (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions. Orphan is a privately-held, Toronto-based specialty pharmaceutical company that in-licenses therapies for rare disorders and specialty medicines for the Canadian market.
Knight Expands Team
Marketwire - Tue Aug 26, 7:04AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

announced today (1) the appointment of Amal Khouri to the position of Vice President of Business Development and (2) the appointment of Sylvie Tendler to Knight's Board of Directors. "Both Amal and Sylvie are proven pharmaceutical executives and expand our capacity to secure the rights to innovative pharmaceuticals that improve the health of Canadians", said Jonathan Ross Goodman, President and CEO of Knight.
Knight Reports Second Quarter 2014 Results
Marketwire - Thu Aug 14, 5:01AM CDT
Knight Therapeutics Inc. ("Knight"

(TSX: GUD) today reported its financial results for the quarter ended June 30, 2014.
Knight Therapeutics Inc. Hires Advisor to Sell Its Priority Review Voucher
Marketwire - Tue Aug 12, 7:04AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into an arrangement with a global investment banking firm to sell its neglected tropical disease Priority Review Voucher ("PRV"

. The arrangement is effective August 18, 2014.
Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore
Marketwire - Thu Jul 03, 7:38AM CDT
Medicure Inc. ("Medicure" or the "Company"

(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today announced that the Company and its newly formed and wholly owned subsidiary, Medicure U.S.A. Inc. ("Medicure USA"

have entered into an arrangement whereby they have acquired a minority interest in a pharmaceutical manufacturing business. Specifically, Medicure and Medicure USA have acquired a 6.09% equity interest (5.33% on a fully-diluted basis) (the "Ownership Interest"

in two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore"

will be wholly owned operating subsidiaries. Medicure also received an option to acquire all of the remaining issued shares of Apicore LLC and the holding company of Apicore US LLC, within the next 3 years. The Ownership Interest and certain other rights, including the Option Rights described below, were obtained by Medicure for its lead role in structuring a US$22.5 million, majority interest purchase and financing of Apicore (the "Purchase"

by Signet Healthcare Partners ("Signet"

, Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, and investors affiliated with Sanders Morris Harris Inc. ("Sanders"

(collectively, the "Investors"

.
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement to Support the Acquisition of Apicore
Marketwire - Thu Jul 03, 7:21AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement to support the acquisition of two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore"

will be wholly owned operating subsidiaries. The purchase arrangement included a secured loan provided by Knight and Sanders Morris Harris Inc., and an equity investment by Signet Healthcare Partners ("Signet"

for an aggregate amount of US$22.5 million. Medicure Inc. ("Medicure"

acquired a minority interest in Apicore and the founding shareholders of Apicore continue to own a significant minority interest in Apicore.
Knight Therapeutics Inc. Invests in Sectoral Asset Management Inc. for Preferred Access to Canadian Product Rights
Marketwire - Thu Jun 26, 7:03AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a letter of agreement with Sectoral Asset Management Inc. ("Sectoral"

to invest USD$13 million into its New Emerging Medical Opportunities Funds II, Ltd. ("NEMO II"

.
Knight Therapeutics Inc. and Origin Biomed Inc. Sign Secured Debt Financing Agreement
Marketwire - Wed Jun 25, 8:32AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement with privately-held Origin Biomed Inc. ("Origin"

, a company dedicated to the worldwide commercialization of the Neuragen(R) and Bionica brands.
Knight Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto
Marketwire - Wed Jun 18, 1:29AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday June 18, 2014 at 11:30 am ET at the Toronto Board of Trade. A copy of the presentation will be available at www.gud-knight.com.